We’re currently experiencing extremely high call volumes. We’re very sorry for any inconvenience this might cause.

If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Integragen (ALINT) EUR1

Sell:€1.38 Buy:€1.40 Change: €0.075 (5.10%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Change: €0.075 (5.10%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Change: €0.075 (5.10%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Integragen SA is a France-based company active in the healthcare sector. It researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. It uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). It also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The Company also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.

Contact details

Genopole Campus 1
Genavenir 8 5 rue Henri Desbrueres
+33 (1) 60910900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€9.63 million
Shares in issue:
6.47 million
Euronext Paris

Key personnel

  • Bernard Courtieu
    Chairman of the Board, Chief Executive Officer
  • Laurence Riot Lamotte
    Director of Administration and Finance
  • Larry Yost
    Chief Executive Officer - Integragen Inc
  • Francois Liebaert
    Vice President - Research & Development and Medical Affairs
  • Emmanuel Martin
    Director Sales & Marketing for the Services Business Unit
  • Francis Rousseau
    Director of Genomics

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.